Mayne Pharma GroupMAYNF 52 Forward PE Ratio is 22.94 as of Jul. 13, 2026. GuruFocus rates MAYNF with a GF Score™ of 52/100 and a GF Value™ of $3.70 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 51 Medical Distribution companies, Mayne Pharma Group ranks worse than 86.27% on this metric.
Mayne Pharma Group (OTCPK:MAYNF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Mayne Pharma Group Forward PE Ratio Related Terms
Mayne Pharma Group Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group Forward PE Ratio Chart
Mayne Pharma Group Annual Data
Trend
2016-06
2017-06
2018-06
2019-06
2020-06
Forward PE Ratio
22.32
12.30
18.38
19.80
22.22
Mayne Pharma Group Semi-Annual Data
2015-12
2016-06
2016-12
2017-06
2017-12
2018-06
2018-12
2019-06
2020-06
2020-12
2021-12
Forward PE Ratio
28.57
22.32
14.39
12.30
12.77
18.38
18.52
19.80
22.22
49.26
285.71
MAYNF vs MCK, CAH, COR: Forward PE Ratio Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Forward PE Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Mayne Pharma Group (MAYNF) has a Forward PE Ratio of 22.94 as of Jul. 13, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #44 out of 51 companies in the Medical Distribution industry, placing it in the top 86.3%.
Is Mayne Pharma Group's Forward PE Ratio too high?
Mayne Pharma Group's current Forward PE Ratio is 22.94. The Medical Distribution industry median Forward PE Ratio is 14.53. Mayne Pharma Group's value of 22.94 is 57.9% above this industry median. Based on the distribution chart, Mayne Pharma Group ranks #44 out of 51 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Forward PE Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #44 out of 51 companies for Forward PE Ratio. This places Mayne Pharma Group in the lower half of its industry. The industry median Forward PE Ratio is 14.53. Mayne Pharma Group's value of 22.94 is 57.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Distribution company?
The median Forward PE Ratio among Medical Distribution companies is 14.53, based on 51 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayne Pharma Group's current Forward PE Ratio of 22.94 is 57.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Forward PE Ratio is 14.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Forward PE Ratio is 22.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.70, compared to a current price of $1.97 — trading 46.7% below its estimated fair value. The current Forward PE Ratio is 22.94 and 57.9% above the Medical Distribution industry median of 14.53. Mayne Pharma Group's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Forward PE Ratio is 22.94 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (MAYNF) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of $1.97 is trading 46.7% below its estimated GF Value™ of $3.70.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for MAYNF:
Forward PE Ratio: 22.94
GF Value™: $3.70 vs. price of $1.97 (46.7% below fair value)
Industry Position: 57.9% above the Medical Distribution median (#44 of 51)
No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
52GF Score
Get the complete analysis for MAYNF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAYNF has been successfully added to your 